Home - Medical Policies - Alabama
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing Management
- Hemophilia Drug Management
- Medical Policies
- PET, MRI, MRA, CT, CTA/CCTA
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy Management (RTM)
- Self-Administered Drug Policies
- Transgender Services
Current Genetic Testing Policies
Effective January 1, 2020, Blue Cross and Blue Shield of Alabama will partner with AIM Specialty Health®, an independent company, to administer genetic testing solutions for our customers.
Third Party Disclaimer
You are about to leave Blue Cross and Blue Shield of Alabama’s website and enter a website operated by AIM Specialty Health® (AIM). AIM is our business associate and is an independent company that provides diagnostic testing, information and services. AIM has agreed to follow Blue Cross' privacy and security policies regarding the confidentiality and protection of your personal health information.
To continue to the AIM Specialty Health website, click "Accept” below.
Genetic Testing
For Medicare Local or National Coverage Determinations (LCD/NCD) click here.
Blue Advantage will follow Palmetto GBA MolDX* when there is no Local Coverage Determination or National Coverage Determination related to a Molecular Diagnostic Test.